Cerepro (Choline alfoscerate) capsules
24484USD

Cerepro (Choline alfoscerate) capsules

SKU:2332
To favorites
Cerepro (Choline alfoscerate) nootropic agent, enhances metabolic processes and activates the structures of the reticular formation of the brain
Active substance:Choline alfoscerate
Pharmacological group:Nootropic
Formulation:Capsules
Dosage mg:400
In stock
In stock
$44
11
Description
Features
Reviews

Instructions for Cerepro (Choline alfoscerate) capsules

English product name
Cerepro

Release Form
caps. 400 mg: 14 pcs

Description Cerepro

The capsules are soft gelatine, from red to brown, and are oblong; the capsule contents are oily, transparent, colourless or slightly coloured liquid.

1 cap.
choline alfoscerate (glyceryl phosphorylcholine hydrate) 400 mg
Auxiliary substances: glycerol (glycerin), water purified.

The capsule envelop comprises: medical gelatin, glycerol (glycerin), methylparahydroxybenzoate (methylparaben), propyl parahydroxybenzoate (propyl paraben), iron oxide red dye, titanium dioxide, purified water, sorbitol (sorbitol).

14 pcs. - blister packs (1) - cardboard packs.

ATC codes
N07AX02 Choline alfoscerate

Clinical-pharmacological groups / Group affiliation
Nootropic drug. Central Action Cholinomimetic

Active substance
choline alfoscerate (glyceryl phosphorylcholine hydrate)

Pharmaco-therapeutic group Cerepro

Nootropic agent

Pharmacological effect Cerepro

Holinomimetic. It is a precursor to acetylcholine. It mainly affects cholinergic receptors in the CNS. Glycerophosphate, which is formed by cleavage of the choline alfoscerate, is a precursor to the phospholipids (phosphatidylcholine) of the neuron membrane. It facilitates the transmission of nerve impulses in cholinergic neurons, improves the plasticity of neuronal membranes and the function of receptors.

Testimony Cerepro

  • Acute period of head trauma with mainly stem level of lesions, 
  • chronic cerebrovascular insufficiency (discirculatory encephalopathy);
  • dementia syndrome of various genesis, 
  • including Alzheimer's disease; 
  • ischemic stroke (early and late recovery period); 
  • Gettington's chorea; 
  • senile pseudomelancholy.

Method of use, course and dosage

Inside: 400 mg three times a day, treatment course three - six months

  • Nosology (ICD codes)
  • F00
  • Dementia in Alzheimer's
  • F01
  • Vascular dementia
  • F03
  • Dementia unspecified
  • F07
  • Personality and behavioural disorders caused by disease, damage or brain dysfunction
  • G10
  • Guentington Chorea
  • G93.4
  • Encephalopathy unrefined
  • I63
  • Brain infarction
  • S06
  • Intracranial injury
Features
Active substance
Pharmacological group
Formulation
Dosage mg
Country of origin
Expiration Date
No reviews yet — your comment may be first.
All reviews 0
general rating
Analogues
Logacer (Choline alfoscerate) solution 250 mg
SKU:2342
$27
In stock
Cereton (Choline alfoscerate) solution 250 mg
SKU:2340
$26
In stock
Cereton (Choline alfoscerate)
SKU:2337
$33
In stock
Holitilin (Choline alfoscerate) 400 mg
SKU:2335
$36
In stock